The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Aims to achieve CDMO sales of US$ 400 million by 2028
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
USFDA completes PAI of Lupin’s biotech facility in Pune
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The net-zero target approval complements the company's near-term emission reduction targets
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Subscribe To Our Newsletter & Stay Updated
